New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

What it owns vs. what it owes End of fiscal 2026, Jun 30, 2026

Shareholders’ equity is 37.1% of the balance sheet. What is a balance sheet?

Jun 30, 2026 · total $40.8M

Owns

$25.9MLong-term assets
$12.1MOther short-term assets
$2.8MCash & short-term investments

Funded by

$15.2MShareholders’ equity
$25.7MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 37.1%.

Jun '24 Jun '25 Jun '26
Total current assets
14.98 25.81 14.88
Total non-current assets
32.26 30.20 25.93
Total Assets
47.24 56.01 40.81
Total current liabilities
11.53 9.67 12.83
Total non-current liabilities
17.78 18.57 12.84
Total liabilities
29.30 28.24 25.66
Common Equity (Total)
17.94 27.76 15.15
Shareholders Equity (Total)
17.94 27.76 15.15

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026